Fracture must have been demonstrated radiologically and the year of plain x-ray, CT or MRI scan must be documented in the patient’s medical records when treatment is initiated. A vertebral fracture is defined as a reduction in height of the anterior or mid portion of a vertebral body relative ≥20% to the posterior height of that body or a 20% reduction in any of these heights compared to the vertebral body ≥ above or below the affected vertebral body 35 mg + 1.25g N/A For preservation of bone mineral density in patients on long-term glucocorticoid therapy patients are undergoing <-1.0 (enteric coated) continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic. 4122 Corticosteroid-induced osteoporosis in a patient currently on long-term (≥ 3 months), high-dose (7.5 mg/day ≤-1.5 prednisolone or equivalent) corticosteroid therapy. 4117 Osteoporosis in a patient aged 70 or older. ≤-3.0 Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. 4123 Established osteoporosis in a patient with fracture due to minimal trauma. N/A Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition.
Fracture must have been demonstrated radiologically and the year of plain x-ray, CT or MRI scan must be documented in the patient’s medical records when treatment is initiated. A vertebral fracture is defined as a ≥20% reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body or a ≥ 20% reduction in any of these heights compared to the vertebral body above or below the affected vertebral body 35 mg + 1.25g (enteric coated) N/A For preservation of bone mineral density in patients on long-term glucocorticoid therapy patients are undergoing continuous treatment with a dose equal to or greater than 7.5 mg of prednisone or equivalent per day. Prescribers need to demonstrate that the patient has been on continuous therapy for 3 months or more and demonstrate that the patient is osteopenic. <-1.0 4122 Corticosteroid-induced osteoporosis in a patient currently on long-term (≥ 3 months), high-dose (7.5 mg/day prednisolone or equivalent) corticosteroid therapy. ≤-1.5 4117 Osteoporosis in a patient aged 70 or older. Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. ≤-3.0 4123 Established osteoporosis in a patient with fracture due to minimal trauma. Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. N/A
App1313-FinalDAP-accessible.docx